Release date: 2014-08-22
According to Japan’s Asahi Shimbun reported on August 18, Japan’s New Energy Industry Technology Development Agency (NEDO) and the National Cancer Research Center announced on the 18th that they will begin to study 13 blood tests to determine 13 cancers and dementias. Laboratory technology. The R&D staff plans to continue the development work until 2018 and then apply it to the physical examination.
According to NEDO, the project requires about 7.9 billion yen (about 473 million yuan). Researchers will investigate the presence of "microRNA" substances in the blood, which have more than 2,500 species in the human body. In recent years, scientific research has found that the types and amounts of "microRNA" substances in the blood vary with the disease.
The 13 target cancers are cancers such as stomach cancer, colon cancer, lung cancer, liver cancer, and breast cancer. The researchers will investigate the blood of patients preserved at the National Cancer Research Center and the National Longevity Medical Research Center to find the "microRNAs" unique to each disease.
So far, screening for cancer has mainly detected tumor markers by blood sampling, but in many cases, cancer cannot be detected without developing to a certain extent. "MicroRNAs" are also secreted when cancer cells are smaller, and researchers believe this may help early detection of cancer.
"There is no need to draw blood to test various cancers, which will reduce the patient's physical burden. I hope this technology can be put into use soon," said Naoya Hiroyuki, head of the National Cancer Research Center of Japan.
Source: International Online
Disposable Tourniquet Roll Packed 23M
Best Tourniquet,Tourniquet Online,Disposable Tourniquet,Tourniquet For Blood Draw
GUANGDONG JIANGMEN RONGHAI MEDICAL TECHNOLOGY CO.,LTD , https://www.kimaomedical.com